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Editorial Comment
The Development of
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The historical note in this issue of the Journal (I) on the
contribution of Agress to the subject of coronary throm-
bolysis is an interesting footnote in the development of
thrombolytic therapy. However, the author has magnified
the significance of the observation to the formative phase
of this new form of therapy.
The two seminal observations that opened up a new field
of investigation in the development of thrombolytic therapy
were I) the demonstration in 1949 that extravascular clots
in humans could be dissolved readily by the local instillation
of streptokinase (2), and 2) the demonstration in 1952 that
clot dissolution could be extended to experimentally induced
thrombi in rabbit ear veins by the intravenous infusion of
streptokinase (3). Once the lysis of an intravascular throm-
bus could be achieved by the systemic administration of a
thrombolytic agent, the race was on to achieve an acceptable
therapy for the dissolution of human thrombi. t
The developmental work, which was now attracting other
investigators as well as spurring evaluation of several po-
tential thrombolytic agents, required experimental models
in which clot lysis could be readily observed and in which
appropriate hematologic studies could be carried out. Con-
sequently, in the 1952 to 1954 period, several reports ap-
peared describing observations made in experimentally in-
duced thrombotic occlusions in the peripheral arteries and
veins of animals using streptokinase (6), chymotrypsin (6),
trypsin (6-9) and a "human plasmin" preparation (10); the
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t At that time, acute coronary thrombosis (a term used synonymously
with acute myocardial infarction) accounted for the largest number of
admissions to an adult medical ward and was associated with an in-hospital
mortality rate of approximately 30%. Therefore the primary goal for sys-
temic thrombolytic therapy was to apply it to the treatment of acute coronary
thrombosis. The delay in initiating such a study by my group (4,5) was
related only to the need to wait until a highly purified preparation of
streptokinase with relatively few side effects was made available by Lederle
Laboratories.
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latter was a streptokinase-plasminogen mixture that in con-
trast to streptokinase, proved to be a very powerful activator
of all animal plasminogens (6).
Trypsin, the subject of the Agress experiment, soon was
discarded as a viable thrombolytic agent. At low levels of
activity, it converted prothrombin to thrombin and caused
clotting; at high levels of activity, it degraded a wide variety
of plasma proteins. Furthermore, preformed thrombi were
not lysed when trypsin was infused intravenously (6,8,9);
dissolution only occurred when the thrombus was formed
in the presence of trypsin (8).
In the Agress experiment, the embolized fibrin clots were
not dissolved by the trypsin infusions. Rather. the difference
between the control and treated animals was the presence
of new thrombi surrounding the fibrin emboli in the coronary
vessels of the control animals and their absence in the tryp-
sin-treated animals. Thus, the presumed formation and sub-
sequent disappearance of thrombi in the trypsin-treated an-
imals occurred after the start of the trypsin infusions.
Consequently, the experiment did not establish that a pre-
formed coronary thrombus could be lysed.
The experimental model created by Agress did represent
a novel attempt to employ an animal prototype for the study
of coronary thrombolysis at a time when open chest surgery
would have been associated with a very high mortality.
However, the randomness of the embolization with its en-
suing multiple small infarcts did not emulate the clinical
situation in which complete occlusion of a major artery is
present with an associated transmural infarct. For this rea-
son, and because of the deficiencies in quantitating infarct
size, the model never represented a significant advance in
experimental design.
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